EMR Stock Analysis: Emerson Electric | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 91.572m USD | 12M Return: 28.5% | US2910111044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 471M
EPS Trend: 98.6%
Qual. Beats: 0
Rev. Trend: 96.4%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Emerson Electric Co. (NYSE: EMR) is a global technology and software company headquartered in Saint Louis, Missouri, and incorporated in 1890. It operates through six segments-Final Control, Measurement & Analytical, Discrete Automation, Safety & Productivity, Control Systems & Software, and Test & Measurement-serving customers across the Americas, Asia, the Middle East, Africa, and Europe. The companys portfolio spans industrial process valves and regulators (Fisher, Anderson Greenwood, Crosby), intelligent instrumentation (Rosemount, Micro Motion, Flexim), pneumatic and motion components (ASCO, Aventics, Afag), professional and consumer tools (RIDGID, Greenlee, Klauke), process control software (DeltaV, Ovation), and automated test systems.
Emerson operates within the Industrials sector (Electrical Components & Equipment), serving both process industries-such as oil & gas, chemicals, and power-and discrete manufacturing customers. Its business model blends hardware sales (valves, instruments, tools) with recurring software and automation revenue through its Control Systems & Software segment, positioning the company to benefit from ongoing investment in industrial automation and digital transformation across global manufacturing.
- Test & Measurement segment margins expand on NI software demand
- Final Control backlog growth signals strong process industry capex
- Discrete Automation margins pressured by Aventics inventory adjustments
- Safety & Productivity demand softens amid weaker professional tool spending
| Net Income: 2.69b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.10 > 1.0 |
| NWC/Revenue: -3.17% < 20% (prev -6.74%; Δ 3.57% < -1%) |
| CFO/TA 0.10 > 3% & CFO 3.98b > Net Income 2.69b |
| Net Debt (11.1b) to EBITDA (5.35b): 2.07 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (559.7m) vs 12m ago -1.03% < -2% |
| Gross Margin: 53.36% > 18% (prev 52.83%; Δ 0.52% > 0.5%) |
| Asset Turnover: 45.31% > 50% (prev 42.93%; Δ 2.39% > 0%) |
| Interest Coverage Ratio: 9.99 > 6 (EBIT TTM 3.87b / Interest Expense TTM 387.0m) |
| A: -0.01 (Total Current Assets 9.52b - Total Current Liabilities 10.1b) / Total Assets 41.8b |
| B: 1.00 (Retained Earnings 41.8b / Total Assets 41.8b) |
| C: 0.09 (EBIT TTM 3.87b / Avg Total Assets 41.9b) |
| D: 0.98 (Book Value of Equity 20.7b / Total Liabilities 21.1b) |
| Altman-Z'' = 4.82 = AA |
| DSRI: 1.02 (Receivables 3.32b/3.10b, Revenue 19.0b/18.0b) |
| GMI: 0.99 (GM 52.83% / 53.36%) |
| AQI: 0.99 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.05 (Revenue 19.0b / 18.0b) |
| TATA: -0.03 (NI 2.69b - CFO 3.98b) / TA 41.8b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of November 17, 2026, the stock is trading at USD 160.65 with a total of 2,513,845 shares traded. Over the past week, the price has changed by -4.89%, over one month by -0.15%, over three months by -0.51% and over the past year by +28.46%.
Current recommended Stop Loss: 150.00 (which is 6.6% or 2.1 ATR below the current price).
Emerson Electric has received a consensus analysts rating of 4.07. Therefore, it is recommended to buy EMR.
- StrongBuy: 16
- Buy: 4
- Hold: 8
- Sell: 0
- StrongSell: 2
| Analysts Target Price | 182.8 | 13.8% |
P/E Trailing = 34.8476
P/E Forward = 23.0415
P/S = 4.8242
P/B = 4.419
P/EG = 2.0213
Revenue TTM = 19.0b USD
EBIT TTM = 3.87b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 7.51b USD (from longTermDebt, last quarter)
Short Term Debt = 4.67b USD (from shortTermDebt, last quarter)
Debt = 12.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 694.0m
Net Debt = 11.1b USD (calculated: Debt 12.9b - CCE 1.81b)
Enterprise Value = 103b USD (91.6b + Debt 12.9b - CCE 1.81b)
Interest Coverage Ratio = 9.99 (Ebit TTM 3.87b / Interest Expense TTM 387.0m)
EV/FCF = 29.03x (Enterprise Value 103b / FCF TTM 3.54b)
FCF Yield = 3.44% (FCF TTM 3.54b / Enterprise Value 103b)
FCF Margin = 18.62% (FCF TTM 3.54b / Revenue TTM 19.0b)
Net Margin = 14.14% (Net Income TTM 2.69b / Revenue TTM 19.0b)
Gross Margin = 53.36% ((Revenue TTM 19.0b - Cost of Revenue TTM 8.85b) / Revenue TTM)
Gross Margin QoQ = 52.68% (prev 54.48%)
Tobins Q-Ratio = 2.45 (Enterprise Value 103b / Total Assets 41.8b)
Interest Expense / Debt = 3.01% (Interest Expense 387.0m / Debt 12.9b)
Taxrate = 22.84% (795.0m / 3.48b)
NOPAT = 2.98b (EBIT 3.87b * (1 - 22.84%))
Current Ratio = 0.94 (Total Current Assets 9.52b / Total Current Liabilities 10.1b)
Debt / Equity = 0.62 (Debt 12.9b / totalStockholderEquity, last quarter 20.7b)
Debt / EBITDA = 2.07 (Net Debt 11.1b / EBITDA 5.35b)
Debt / FCF = 3.13 (Net Debt 11.1b / FCF TTM 3.54b)
Total Stockholder Equity = 20.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.41% (Net Income 2.69b / Total Assets 41.8b)
RoE = 13.14% (Net Income TTM 2.69b / Total Stockholder Equity 20.4b)
RoCE = 13.85% (EBIT 3.87b / Capital Employed (Equity 20.4b + L.T.Debt 7.51b))
RoIC = 8.43% (NOPAT 2.98b / Invested Capital 35.4b)
WACC = 9.47% (E(91.6b)/V(104b) * Re(10.48%) + D(12.9b)/V(104b) * Rd(3.01%) * (1-Tc(0.23)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.68 | Cagr: -1.18%
[DCF] Terminal Value 74.42% ; FCFF base≈3.19b ; Y1≈3.65b ; Y5≈5.38b
[DCF] Fair Price = 103.0 (EV 67.5b - Net Debt 11.1b = Equity 56.5b / Shares 548.6m; r=9.47% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.64 | EPS CAGR: 10.01% | SUE: 0.28 | # QB: 0
Revenue Correlation: 96.41 | Revenue CAGR: 5.52% | SUE: 1.57 | # QB: 2
EPS current Quarter (2026-12-31): EPS=1.62 | Chg30d=-0.27% | Revisions=-73% | Analysts=22
EPS next Quarter (2027-03-31): EPS=1.73 | Chg30d=-0.16% | Revisions=-62% | Analysts=21
EPS current Year (2027-09-30): EPS=7.31 | Chg30d=+0.55% | Revisions=-5% | GrowthEPS=+11.0% | GrowthRev=+5.4%
EPS next Year (2028-09-30): EPS=8.03 | Chg30d=+0.03% | Revisions=+0% | GrowthEPS=+9.8% | GrowthRev=+5.2%
[Analyst] Revisions Ratio: -34% (up=15, down=32)